The Impact of microRNAs in Breast Cancer Angiogenesis and Progression.


Journal

MicroRNA (Shariqah, United Arab Emirates)
ISSN: 2211-5374
Titre abrégé: Microrna
Pays: United Arab Emirates
ID NLM: 101631045

Informations de publication

Date de publication:
2019
Historique:
received: 07 03 2018
revised: 22 03 2018
accepted: 11 10 2018
pubmed: 20 10 2018
medline: 24 4 2019
entrez: 19 10 2018
Statut: ppublish

Résumé

The study aims to review the recent data considering the expression profile and the role of microRNAs in breast tumorigenesis, and their impact on -the vital for breast cancer progression- angiogenesis. PubMed was searched for studies focused on data that associate microRNA with breast cancer, using the terms ''breast", "mammary gland", "neoplasia'', "angiogenesis" and ''microRNA'' between 1997-2018. Aberrant expression of several circulating and tissue miRNAs is observed in human breast neoplasms with the deregulation of several miRNAs having a major participation in breast cancer progression. Angiogenesis seems to be directly affected by either overexpression or down regulation of many miRNAs, defining the overall prognostic rates. Many miRNAs differentially expressed in breast cancer that reveal a key role in suppression - progression and metastasis of breast cancer along with the contribution of the EGF, TNF-a and EGF cytokines. Conclusion Angiogenesis has proven to be vital for tumor development and metastasis while microRNAs are proposed to have multiple biological roles, including participation in immunosuppressive, immunomodulatory and recent studies reveal their implication in angiogenesis and its possible use as prognostic factors in cancer Even though larger studies are needed in order to reach safe conclusions, important steps are made that reveal the connection of serum microRNA expression to the angiogenic course of breast cancer, while miRNAs could be potential prognostic factors for the different breast cancer types.

Identifiants

pubmed: 30332982
pii: MIRNA-EPUB-93770
doi: 10.2174/2211536607666181017122921
doi:

Substances chimiques

MicroRNAs 0
Receptors, Estrogen 0
Receptors, Progesterone 0
ERBB2 protein, human EC 2.7.10.1
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101-109

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Auteurs

Emmanuel N. Kontomanolis (EN)

Department of Obstetrics & Gynecology, Democritus University in Alexandroupolis, Dragana, Greece.

Zacharias Fasoulakis (Z)

Department of Obstetrics & Gynecology, Democritus University in Alexandroupolis, Dragana, Greece.

Valentinos Papamanolis (V)

Department of Obstetrics & Gynecology, General Hospital of Korinthos, Corinth, Greece.

Sofia Koliantzaki (S)

Department of Obstetrics & Gynecology, General Hospital of Korinthos, Corinth, Greece.

Georgios Dimopoulos (G)

Department of Obstetrics & Gynecology, General Hospital of Korinthos, Corinth, Greece.

Nikolaos J. Kambas (NJ)

Department of Obstetrics & Gynecology, General Hospital of Korinthos, Corinth, Greece.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH